Lucentis receives DME approval in the EU

Article

Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME).

Novartis has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its therapy Lucentis for the treatment of patients with diabetic macular oedema (DME).

The company had supporting data from two clinical trials, RESTORE and RESOLVE, which demonstrated that Lucentis provided rapid and sustained visual acuity gains in comparison with sham or laser therapy.

David Epstein, division head of Novartis Pharmaceuticals, commented, "Lucentis was designed specifically for use in the eye, and its efficiency and safety have now been demonstrated in patients suffering loss of vision due to diabetic macular oedema through a robust programme of clinical trials."

In addition to the company supported clinical trials, a further study conducted by the Diabetic Retinopathy Clinical Research Network (DRCR.net) also demonstrated gains in visual acuity after two years of treatment with Lucentis.

Recent Videos
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Elizabeth Cohen, MD, discusses the Zoster Eye Disease study at the 2024 AAO meeting
Victoria L Tseng, MD, PhD, professor of ophthalmology and glaucoma specialist, UCLA
Brent Kramer, MD, of Vance Thompson Vision speaks at the 2024 AAO meeting
© 2025 MJH Life Sciences

All rights reserved.